GlassScriptPhysician profile
Shruti Vyas
NPI 1164919627
$4,869.03
in general payments reported to CMS, 2019-2025
21 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $602 · 2023: $2,479 · 2024: $614 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Travel and Lodging: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.36 |
| Travel and Lodging | $1,331.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,679.39 | 2021-2025 | Prostep, Salvation, Citrefix |
| Kerecis Limited | $781.06 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Bioventus LLC | $185.89 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $151.14 | 2021-2025 | Stravix Pl |
| Biocomposites INC | $149.41 | 2023 | Stimulan |
| Sanara Medtech INC. | $149.30 | 2023 | Celleraterx |
| Access Pro Medical, LLC | $139.83 | 2022-2025 | Matriderm |
| Horizon Therapeutics Plc | $119.46 | 2022 | |
| Innovation Technologies INC | $110.00 | 2025 | Irrisept |
| Integra Lifesciences Corporation | $81.84 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Flower Orthopedics Coporation | $74.93 | 2023-2024 | |
| Lifenet Health | $45.68 | 2024 | Theragenesis Wound Matrix |
| Linvatec Corporation | $42.88 | 2023 | 5ms, Colink 2, Colink Afx |
| Inari Medical, INC. | $35.89 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Corcept Therapeutics | $25.78 | 2025 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $20.12 | 2022 | |
| Averitas Pharma INC. | $18.52 | 2023 | Qutenza |
| Novo Nordisk INC | $16.27 | 2024 | Ozempic, Rybelsus |
| Convatec INC. | $15.32 | 2023 | |
| Sebela Pharmaceuticals INC. | $13.45 | 2023 | Naftin |
| Boston Scientific Corporation | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.